{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:19:20Z","timestamp":1785860360699,"version":"3.56.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Hematology\/Oncology Nursing"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Children with relapsed\/refractory (R\/R) neuroblastoma are at risk for poor outcomes due to resistant disease. Naxitamab is an anti-glycolipid disialoganglioside (GD2) monoclonal antibody approved by the Food and Drug Administration for the treatment of R\/R high-risk neuroblastoma. Serious adverse reactions are an expected part of treatment and include severe nerve pain during the infusion. Institutions using an interdisciplinary team approach can create a safe system for the infusion of naxitamab in the outpatient clinic setting. The purpose of this article is to present this immunotherapy, naxitamab, its adverse events (AEs), and one institution\u2019s approach in administering naxitamab in an outpatient infusion center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>An interdisciplinary team, led by a pediatric oncology advanced practice nurse, developed a detailed standardized care plan that can be tailored to the patient's previous history with pain medications and response to naxitamab. The team includes multiple nursing roles, physician specialists, pharmacists, psychosocial staff, and the patient and family; each team member is educated in their defined role.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AEs can be effectively managed, and naxitamab infusions can be safely infused in the outpatient infusion center through repeated cycles of treatment. Patients can be discharged to home 2 hr after the completion of the infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Outpatient administration of naxitamab requires exact planning and implementation by a well-prepared interdisciplinary team. This approach supports patients and families in maximizing their quality of life through ambulatory care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/27527530251410910","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:50:19Z","timestamp":1771523419000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Naxitamab for Relapsed\/Refractory Neuroblastoma"],"prefix":"10.1177","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-6572","authenticated-orcid":false,"given":"Teresa","family":"Herriage","sequence":"first","affiliation":[{"name":"Children\u2019s Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawhar","family":"Rawwas","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sterman","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hennen","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bevers","sequence":"additional","affiliation":[{"name":"Children\u2019s Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Pediatric advanced life support manual","author":"American Heart Association","year":"2020","unstructured":"American Heart Association. (2020). Pediatric advanced life support manual."},{"key":"e_1_3_3_3_1","unstructured":"Association of Pediatric Hematology\/Oncology Nurses. (2025). Member discussion boards on naxitamab. https:\/\/www.aphon.org\/members\/member-connection\/"},{"issue":"7","key":"e_1_3_3_4_1","article-title":"Clinical uses of ketamine in children: A narrative review","volume":"14","author":"Bali A.","year":"2022","unstructured":"Bali A., Dang A., Gonzalez D., Kumar R., Asif S. (2022). Clinical uses of ketamine in children: A narrative review. Cureus, 14(7),Article e27065. https:\/\/doi.org\/10.7759\/cureus.27065","journal-title":"Cureus"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00544-9"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100462"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030358"},{"key":"e_1_3_3_8_1","volume-title":"APHON chemotherapy and biotherapy curriculum","author":"Herring R.","year":"2019","unstructured":"Herring R. (Ed.). (2019). APHON chemotherapy and biotherapy curriculum (4th ed.). Association of Pediatric Hematology\/Oncology Nurses.","edition":"4"},{"issue":"8","key":"e_1_3_3_9_1","article-title":"Treatment of high-risk neuroblastoma","volume":"10","author":"Krystal J.","year":"2023","unstructured":"Krystal J., Foster J. H. (2023). Treatment of high-risk neuroblastoma. Children (Basel), 10(8),Article 1302. https:\/\/doi.org\/10.3390\/children10081302","journal-title":"Children (Basel)"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143729"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.13429"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092535"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1627"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194837"},{"key":"e_1_3_3_15_1","unstructured":"National Cancer Institute. (2025). Neuroblastoma treatment (PDQ\u00ae)\u2014Health professional version. https:\/\/www.cancer.gov\/types\/neuroblastoma\/hp\/neuroblastoma-treatment-pdq#_214"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1043454216668825"},{"issue":"5","key":"e_1_3_3_17_1","first-page":"456","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine and the American Society of Anesthesiologists","volume":"43","author":"Schwenk E. S.","year":"2018","unstructured":"Schwenk E. S., Viscusi E. R., Buvanendran A., Hurley R. W., Wasan A. D., Narouze S., Bhatia A., Davis F. N., Hooten W. M., Cohen S. P., (2018). Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine and the American Society of Anesthesiologists. Regional Anesthesia & Pain Medicine, 43(5), 456\u2013466. https:\/\/doi.org\/10.1097\/AAP.0000000000000806","journal-title":"Regional Anesthesia & Pain Medicine"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-015-0515-4"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.11.3343691"},{"key":"e_1_3_3_20_1","unstructured":"U.S. Food and Drug Administration. (2020a). Naxitamab-gqgk (Danyelza) injection for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761171lbl.pdf"},{"key":"e_1_3_3_21_1","unstructured":"U.S. Food and Drug Administration. (2020b). FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1164949"},{"key":"e_1_3_3_23_1","unstructured":"Y-mAbs Therapeutics. (2024) Danyelza: Mechanism of action. https:\/\/danyelza.com\/"}],"container-title":["Journal of Pediatric Hematology\/Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27527530251410910","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/27527530251410910","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27527530251410910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:16:34Z","timestamp":1781694994000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/27527530251410910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1177\/27527530251410910"],"URL":"https:\/\/doi.org\/10.1177\/27527530251410910","relation":{},"ISSN":["2752-7530","2752-7549"],"issn-type":[{"value":"2752-7530","type":"print"},{"value":"2752-7549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}